DNL593 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyna
Phase 1/2 · Frontotemporal Dementia |
DNLI Denali Therapeutics Inc. | DNL593 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|